Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer

Lidia Moyano-Galceran; Elina A. Pietila; S. Pauliina Turunen; Sara Corvigno; Elisabet Hjerpe; Daria Bulanova; Ulrika Joneborg; Twana Alkasalias; Yuichiro Miki; Masakazu Yashiro; Anastasiya Chernenko; Joonas Jukonen; Madhurendra Singh; Hanna Dahlstrand; Joseph W. Carlson; Kaisa Lehti

doi:10.15252/emmm.201911177

Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer

Lidia Moyano-Galceran, Elina A. Pietila, S. Pauliina Turunen, Sara Corvigno, Elisabet Hjerpe, Daria Bulanova, Ulrika Joneborg, Twana Alkasalias, Yuichiro Miki, Masakazu Yashiro, Anastasiya Chernenko, Joonas Jukonen, Madhurendra Singh, Hanna Dahlstrand, Joseph W. Carlson, Kaisa Lehti

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Artikelnummer	11177
Tidskrift	EMBO molecular medicine
Volym	12
Nummer	4
Antal sidor	22
ISSN	1757-4676
DOI	https://doi.org/10.15252/emmm.201911177
Status	Publicerad - apr. 2020
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.15252/emmm.201911177

emmm.201911177Slutlig publicerad version, 4,44 MBLicens: CC BY

Citera det här

Moyano-Galceran, L., Pietila, E. A., Turunen, S. P., Corvigno, S., Hjerpe, E., Bulanova, D., Joneborg, U., Alkasalias, T., Miki, Y., Yashiro, M., Chernenko, A., Jukonen, J., Singh, M., Dahlstrand, H., Carlson, J. W., & Lehti, K. (2020). Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. EMBO molecular medicine, 12(4), Artikel 11177. https://doi.org/10.15252/emmm.201911177

@article{180f85bcb98146b9a49d1ceccc819ebb,

title = "Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer",

keywords = "chemotherapy, EphA2, GPRC5A, HGSC, resistance, TO-MESENCHYMAL TRANSITION, 1ST-LINE TREATMENT, TUMOR-SUPPRESSOR, BREAST-CANCER, DOUBLE-BLIND, EPHA2, INVASION, HETEROGENEITY, METASTASIS, MECHANISMS, 3122 Cancers",

author = "Lidia Moyano-Galceran and Pietila, {Elina A.} and Turunen, {S. Pauliina} and Sara Corvigno and Elisabet Hjerpe and Daria Bulanova and Ulrika Joneborg and Twana Alkasalias and Yuichiro Miki and Masakazu Yashiro and Anastasiya Chernenko and Joonas Jukonen and Madhurendra Singh and Hanna Dahlstrand and Carlson, {Joseph W.} and Kaisa Lehti",

year = "2020",

month = apr,

doi = "10.15252/emmm.201911177",

language = "English",

volume = "12",

journal = "EMBO molecular medicine",

issn = "1757-4676",

publisher = "Wiley",

number = "4",

}

Moyano-Galceran, L, Pietila, EA, Turunen, SP, Corvigno, S, Hjerpe, E, Bulanova, D, Joneborg, U, Alkasalias, T, Miki, Y, Yashiro, M, Chernenko, A , Jukonen, J, Singh, M, Dahlstrand, H, Carlson, JW & Lehti, K 2020, 'Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer', EMBO molecular medicine, vol. 12, nr. 4, 11177. https://doi.org/10.15252/emmm.201911177

TY - JOUR

T1 - Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer

AU - Moyano-Galceran, Lidia

AU - Pietila, Elina A.

AU - Turunen, S. Pauliina

AU - Corvigno, Sara

AU - Hjerpe, Elisabet

AU - Bulanova, Daria

AU - Joneborg, Ulrika

AU - Alkasalias, Twana

AU - Miki, Yuichiro

AU - Yashiro, Masakazu

AU - Chernenko, Anastasiya

AU - Jukonen, Joonas

AU - Singh, Madhurendra

AU - Dahlstrand, Hanna

AU - Carlson, Joseph W.

AU - Lehti, Kaisa

PY - 2020/4

Y1 - 2020/4

KW - chemotherapy

KW - EphA2

KW - GPRC5A

KW - HGSC

KW - resistance

KW - TO-MESENCHYMAL TRANSITION

KW - 1ST-LINE TREATMENT

KW - TUMOR-SUPPRESSOR

KW - BREAST-CANCER

KW - DOUBLE-BLIND

KW - EPHA2

KW - INVASION

KW - HETEROGENEITY

KW - METASTASIS

KW - MECHANISMS

KW - 3122 Cancers

U2 - 10.15252/emmm.201911177

DO - 10.15252/emmm.201911177

M3 - Article

SN - 1757-4676

VL - 12

JO - EMBO molecular medicine

JF - EMBO molecular medicine

IS - 4

M1 - 11177

ER -